285 related articles for article (PubMed ID: 24463035)
21. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
22. Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system.
Barroso-Chinea P; Cruz-Muros I; Afonso-Oramas D; Castro-Hernández J; Salas-Hernández J; Chtarto A; Luis-Ravelo D; Humbert-Claude M; Tenenbaum L; González-Hernández T
Neurobiol Dis; 2016 Apr; 88():44-54. PubMed ID: 26777664
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody.
Chen YH; Yu SJ; Wu KJ; Wang YS; Tsai HM; Liao LW; Chen S; Hsieh W; Chen H; Hsu SC; Chen ML; Hoffer BJ; Wang Y
J Parkinsons Dis; 2020; 10(2):573-590. PubMed ID: 32176654
[TBL] [Abstract][Full Text] [Related]
24. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
von Bohlen und Halbach O; Minichiello L; Unsicker K
FASEB J; 2005 Oct; 19(12):1740-2. PubMed ID: 16037097
[TBL] [Abstract][Full Text] [Related]
25. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
26. Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.
Morales-Prieto N; Bevans R; O'Mahony A; Barron A; Giles Doran C; McCarthy E; Concannon RM; Goulding SR; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
Aging Cell; 2024 Jun; 23(6):e14155. PubMed ID: 38529808
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
28. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
29. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.
Gorbatyuk OS; Li S; Nash K; Gorbatyuk M; Lewin AS; Sullivan LF; Mandel RJ; Chen W; Meyers C; Manfredsson FP; Muzyczka N
Mol Ther; 2010 Aug; 18(8):1450-7. PubMed ID: 20551914
[TBL] [Abstract][Full Text] [Related]
30. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
31. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity.
Liu B; Traini R; Killinger B; Schneider B; Moszczynska A
Exp Neurol; 2013 Sep; 247():359-72. PubMed ID: 23313192
[TBL] [Abstract][Full Text] [Related]
33. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
34. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.
Mosharov EV; Larsen KE; Kanter E; Phillips KA; Wilson K; Schmitz Y; Krantz DE; Kobayashi K; Edwards RH; Sulzer D
Neuron; 2009 Apr; 62(2):218-29. PubMed ID: 19409267
[TBL] [Abstract][Full Text] [Related]
35. Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.
Fischer DL; Manfredsson FP; Kemp CJ; Cole-Strauss A; Lipton JW; Duffy MF; Polinski NK; Steece-Collier K; Collier TJ; Gombash SE; Buhlinger DJ; Sortwell CE
Sci Rep; 2017 Nov; 7(1):16356. PubMed ID: 29180681
[TBL] [Abstract][Full Text] [Related]
36. RNA Interference of Human α-Synuclein in Mouse.
Kim YC; Miller A; Lins LC; Han SW; Keiser MS; Boudreau RL; Davidson BL; Narayanan NS
Front Neurol; 2017; 8():13. PubMed ID: 28197125
[TBL] [Abstract][Full Text] [Related]
37. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
38. Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.
Taschenberger G; Garrido M; Tereshchenko Y; Bähr M; Zweckstetter M; Kügler S
Acta Neuropathol; 2012 May; 123(5):671-83. PubMed ID: 22167382
[TBL] [Abstract][Full Text] [Related]
39. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
40. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
